Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience.

Background: Sarcomatoid carcinomas (SC) are rare tumors with both epithelial and mesenchymal characteristics, linked to aggressive behavior and poor prognosis. Sarcomatoid carcinoma of unknown primary (SCUP) is an exceedingly rare subset with limited literature and no standardized management guidelines. This study aims to characterize the clinical presentations, treatment patterns, and genomic landscape of SCUP.

Aflatoxin awareness and preventive agricultural practices are key to adoption of biocontrol among maize smallholder farmers in Tanzania.

Aflatoxins are toxic secondary metabolites produced by Aspergillus species that infect staple foods like maize causing threat to public health and economic impacts. The use of atoxigenic Aspergillus species is considered one of the promising technologies to prevent aflatoxin contamination in maize. Tanzania approved the use of aflatoxin biocontrol (Aflasafe®) in 2018 and introduced it to eight districts.

Exploring NRB Biofilm Adhesion and Biocorrosion in Oil/Water Recovery Operations Within Pipelines.

Microbially influenced corrosion represents a critical challenge to the integrity and durability of carbon steel infrastructure, particularly in environments conducive to biofilm formation by nitrate-reducing bacteria (NRB). This study investigated the impact of NRB biofilms on biocorrosion processes within oil/water recovery operations in Algerian pipelines. A comprehensive suite of experimental and analytical techniques, including microbial analysis, gravimetric methods, and surface characterization, were employed to elucidate the mechanisms of microbially influenced corrosion (MIC).

Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.

Background: Recurrent squamous cell carcinoma (SCC) of the head and neck (SCCHN) remains a formidable clinical challenge despite available treatments. The phosphatidylinositol 3-kinase (PI3K) pathway has been identified as a potential therapeutic target, and alpelisib, a selective PI3Kα inhibitor, has demonstrated efficacy in certain malignancies. Combining this targeted therapy with immunotherapy has been suggested in previous studies as a promising strategy to bolster the immune response against cancer.